Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||not applicable||AZD3514||Phase I||Actionable||In two Phase I trials, AZD3514 treatment resulted in more than 50% decrease of PSA level in 13% (9/70) of patients with castration-resistant prostate cancer, and an objective soft tissue response in 17% (4/24) of patients in one of the trials (PMID: 25920479).||25920479|